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Background: Psoralen (PSO), a major active component of Psoralea corylifolia, has been shown 
to overcome multidrug resistance in cancer. A drug carrier comprising a lipid-monolayer shell 
and a biodegradable polymer core for sustained delivery and improved efficacy of drug have 
exhibited great potential in efficient treatment of cancers.
Methods: The PSO-loaded lipid polymer hybrid nanoparticles were prepared and character-
ized. In vitro cytotoxicity assay, cellular uptake, cell cycle analysis, detection of ROS level and 
mitochondrial membrane potential (ΔΨm) and western blot were performed. 
Results: The P-LPNs enhanced the cytotoxicity of doxorubicin (DOX) 17-fold compared to 
free DOX in multidrug resistant HepG2/ADR cells. Moreover, P-LPNs displayed pro-apoptotic 
activity, increased levels of ROS and depolarization of ΔΨm. In addition, there were no signifi-
cant effects on cellular uptake of DOX, cell cycle arrest, or the expression of P-glycoprotein. 
Mechanistic studies suggested that P-LPNs enhanced DOX cytotoxicity by increased release 
of cytochrome c and enhanced caspase3 cleavage, causing apoptosis in HepG2/ADR cells.
Conclusion: The lipid-polymer hybrid nanoparticles can be considered a powerful and promis-
ing drug delivery system for effective cancer chemotherapy. 
Keywords: lipid-polymer hybrid nanoparticles, psoralen, drug delivery, HepG2, ADR cells, 
apoptosis
Introduction
Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide.1 
Chemotherapy is frequently used in HCC treatment; however, its efficacy is limited 
by the development of multidrug resistance (MDR).2 Many studies have revealed that 
overexpression of drug efflux pumps, increased DNA damage repair, and hypoxia-
inducible factor1-α (HIF1-α) signaling played important roles in the drug resistance 
of HCC.3–6 In recent years, reduced levels of ROS have also been implicated in cell 
resistance to chemotherapy drugs.7,8 In addition, evidence has been presented that Bcl-2 
over expression resulted in the resistance of cells to doxorubicin (DOX) and pacli-
taxel.9,10 It is clear that multiple factors are involved in conferring multidrug resistance 
and that, regardless of the mechanism, strategies to overcome the phenotype are vital.
In China, Traditional Chinese Medicines have frequently been used for cancer 
treatment. For example, the naturally occurring coumarin compound psoralen (PSO) 
has anti-tumor, estrogen-like, and multidrug resistance modulating properties.11,12 
Unfortunately, its use has been limited by pharmacokinetic issues, primarily due to 
its poor solubility. However, targeted nanoscale drug delivery systems have been 
developed to improve solubility and controlled drug release. More importantly, 
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nanoparticles can bypass efflux pumps since they are inter-
nalized via endocytosis, which ensures higher intracellular 
accumulation of drugs.13–15
Lipid-polymer hybrid nanoparticles (LPNs) com-
bine the advantages of liposome- and polymer-based 
nanoparticles.16,17 The LPNs comprise a polymer core coated 
with lipid layers, and the combination can improve stabil-
ity, enhance cellular uptake, and increase encapsulation 
efficiency.18–20 Poly(D,L-lactide-co-glycolide) (PLGA), a 
biodegradable polymer approved by the US Food and Drug 
Administration, is commonly used as the polymer core to 
encapsulate poorly water soluble compounds.21 The lipid 
component contains natural (eg, crude soybean lipids) and 
synthetic phospholipids such as 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-carboxy (polyethylene glycol) 
2000 (DSPE-PEG
2000
). The amphiphilic phospholipids form 
a monolayer around the hydrophobic polymer core, whereas 
the DSPE-PEG
2000
 embeds in the lipid monolayer to form a 
PEGylation stealth layer outside the lipid shell. This surface 
coating improves electrostatic properties and steric stability 
to prolong circulation half-life.22
In the present work, PSO-loaded lipid-polymer hybrid 
nanoparticles (P-LPNs) were prepared with an emulsification–
solvent–evaporation method. A P-glycoprotein (P-gp) 
expressing DOX-resistant HepG2 (HepG2/ADR) cell was 
used to investigate whether the P-LPNs enhanced the effi-
ciency of chemotherapy drug or showed a superior therapeutic 
effect to free PSO. A thorough understanding about the role 
of P-LPNs on HepG2/ADR cells is of great importance for a 
rational design of nanoparticle-based chemotherapy regimens.
Materials and methods
Materials
Psoralen (PSO) was purchased from Chengdu Pufeide 
Biotechnology Co., Ltd (Chengdu, Sichuang, China). DOX 
hydrochloride was obtained from Selleck Chemicals (Houston, 
TX, USA). Soybean phospholipids (injection grade) were pro-
duced by Shanghai Tywei Pharmaceutical Co., Ltd (Shanghai, 
China). 1,2-distearoyl-sn-glycero-3-phosphocholine-N-
[methoxy (polyethylene glycol)-2000] (DSPE-PEG
2000
) was 
provided by Shanghai AVT Pharmaceutical Technology Co., 
Ltd. (Shanghai, China). Poly(D,L-lactide-co-glycolide) (PLGA, 
50:50, Mw: 8,000–12,000) was obtained from Jinan Daigang 
Biomaterial Co., Ltd (Jinan, Shandong, China). Dimethyl-
sulfoxide (DMSO) and MTT (3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2-H-tetrazolium bromide) were purchased from 
Sigma-Aldrich (St Louis, Missouri, USA). RPMI-1640 cell cul-
ture medium, penicillin–streptomycin, and trypsin-EDTA were 
purchased from Thermo Fisher Life Technologies (Guangzhou, 
Guangdong, China). FBS was provided by AusGeneX Pty Ltd 
(Molendinar, Queensland, Australia). Dialysis membranes 
with a molecular weight cut-off of 8,000–14,000 kDa were 
purchased from Sangon Biotech (Shanghai, China). AnnexinV-
APC dye and SYTOX green dye were provided by KeyGEN 
BioTECH (Nanjing, Jiangsu, China). JC-1 (5,50,6,60-tet-
rachloro-1,10,3,30-tetraethylbenzimidazolyl-carbocyanine 
iodide) and DCFH-DA (2′,7′-dichlorofluorescein diacetate) 
were purchased from Beytime Biotechnology (Shanghai, 
China). Propidium iodide (PI) staining buffer was obtained from 
BD Biosciences Pharmingen (Shanghai, China). P-glycoprotein 
primary antibodies and horseradish peroxidase-conjugated 
goat anti-rabbit immunoglobulin were purchased from Abcam 
(Cambridge, UK). Other primary antibodies were purchased 
from Cell Signaling Technology (Danvers, MA, USA). HepG2 
hepatoblastoma cell lines were provided by KeyGEN BioTECH 
(Nanjing, Jiangsu, China). Ethanol, acetonitrile, and all other 
chemicals were HPLC grade.
Methods
Preparation of the lPNs
LPNs were prepared according to a previously published 
method.22,23 Ester-terminated PLGA and PSO were dissolved 
in acetonitrile, whereas phospholipids and DSPE-PEG
2000
 
dissolved in 4% ethanol solution. The PLGA drug solution 
was added dropwise to the surfactant solution with an oil-water 
ratio of 1:10 (v/v). This solution was stirred for 90 minutes 
at 70°C and formed the core-shell LPN by self-assembly. 
P-LPNs were filtered through a 0.22 µm membrane, then 
used immediately, stored at 4°C, or lyophilized for later use.
size and zeta potential measurements
Particle size, zeta potential, and polydispersity were mea-
sured by dynamic light scattering using a Zetasizer Nano 
ZS90 (Malvern, UK). The dispersion of nanoparticle was 
diluted with ultrapure water and subsequently analyzed.20
Particle morphology
The shape and morphology of NPs was visualized by 
transmission electron microscopy (TEM, TECNAI 10, Philips, 
the Netherlands) using an accelerating voltage of 200 kV. One 
drop of the nanoparticle dispersion was deposited onto the car-
bon-coated copper grid, followed by air drying prior to imaging.24
Encapsulation efficiency and loading capacity
The quantity of PSO in the LPNs was measured by 
HPLC (Agilent, Santa Clara, CA, USA), equipped with 
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a reverse-phase column (Agilent, 150 ×4.6 mm, 5 µm). 
Isocratic chromatography conditions included a mobile 
phase of acetonitrile and water (55:45 v/v) with a flow 
rate of 1.0 mL/min. Injection volume of all samples was 
5 µL. The nanoparticle emulsion was centrifuged at 
11,000 g for 30 minutes to collect free PSO in the superna-
tant. A fraction of the P-LPNs was suspended in the mobile 
phase to determine the total PSO for HPLC analysis.25
The drug loading (DL) and encapsulation efficiency (EE) 
were calculated using the following equations:18,26 
 
EE%
Total Free drug in nanoparticle  mg
Total drug in nano
=
−( )
particle  mg( )
×100%
 
 
DL%
Encapsulated drug  mg
Amount of nanoparticle  mg
= ×
( )
( )
100%.
 
In vitro drug release study
In vitro release of PSO from P-LPNs was done using a stan-
dard dialysis procedure.18 Briefly, 30 mg of the drug loaded 
NPs were dispersed in PBS (0.01 M, pH 7.4) containing 0.5% 
(v/v) Tween-80; the latter added to improve the solubility of 
PSO in PBS. The dispersion, loaded in a dialysis bag, was 
placed into 150 mL PBS and stirred at 100 rpm at 37°C. At 
the indicated times, a 1 mL aliquot of the release medium 
(PBS) was removed for HPLC analysis and replaced with 
the same volume of fresh medium. The release medium was 
exchanged periodically during the dialysis process.
In vitro cell culture
HepG2/S cells were cultured in RPMI-1640 medium supple-
mented with 10% (v/v) FBS and 1% (v/v) penicillin-strep-
tomycin under a humidified 5% CO
2
 atmosphere at 37°C. 
HepG2/ADR cell culture contained 1 µM DOX in RPMI-
1640 medium to maintain P-gp expression every third pas-
sage. Cells were used for experiments at 80% confluency.27
In vitro cytotoxicity assay
Cells were incubated overnight in 96-well plates (Corning 
Inc., Corning, NY, USA) at a cell density of 5×103 cells/well. 
Spent medium was removed and replaced with fresh medium 
containing free DOX, free PSO, P-LPNs, DOX+PSO or 
DOX+P-LPNs, and incubated for 48 hours. Following 
incubation, 20 µL of MTT solution were added to each 
well, and the plates incubated for 4 hours. Absorbance was 
measured at a wavelength of 570 nm using a 96-well plate 
reader (BioTek, Winooski, VT, USA).
Cell toxicity was determined using the following equation:
 
Cell viability (%)
Abs
Abs
sample
control
= ×100%,
 
where Abs
sample
 is the absorbance of cells in the presence 
of different formulations, and Abs
control
 is the absorbance of 
cells in the absence of drug. IC
50
 values were determined 
by nonlinear regression of the general dose–response 
equation.
analysis of cell apoptosis
Cell apoptosis were measured by an AnnexinV-APC & 
SYTOX green apoptosis detection kit according to the 
manufacturer’s instructions. Briefly, HepG2 cells (2×105) 
were placed in 6-well plates (Corning Inc., Corning, NY, 
USA) and cultivated overnight. Medium was then removed 
and replaced by fresh medium containing free DOX, 
DOX+PSO, or DOX+P-LPNs, and incubated for 24 or 
48 hours. Concentrations of DOX was 10 µM, and PSO, 
either in free form or nanoparticles, was 10 and 20 µM, 
respectively. Cells treated with only medium were used as 
a control. The cells were trypsinized, washed with PBS, 
resuspended in 400 µL of binding buffer containing 4 µL of 
APC-conjugated AnnexinV (AnnexinV-APC), and incubated 
in the dark for 10 minutes at ambient temperature. SYTOX 
green stain dye (10 µM) was added, and the samples were 
measured immediately with a flow cytometer (FACSVerse 
BD, San Jose, CA, USA). APC dye (fluorescence channel 4, 
FL4) and SYTOX green dye (fluorescence channel 2, FL2) 
were analyzed as FL2–FL4 dot plots. All observations 
were obtained from three independent experiments, done 
in triplicate.
Cellular uptake of DOX by flow cytometry
Cellular uptake of DOX from the different formulations 
was quantified by flow cytometry. Briefly, HepG2 cells 
(2×105) were placed in 6-well plates overnight. Cells 
were treated with 1 mL of fresh medium containing DOX 
(10 µM), DOX+PSO (20 µM), DOX+P-LPNs (20 µM) or 
DOX+Verapamil (3 µM), and incubated for 3 hours at 37°C. 
Cells treated with only medium were used as the respective 
control. The cells were trypsinized, washed twice in cold 
PBS, and analyzed by flow cytometery (FACSVerse BD).
cell cycle analysis
The distribution of DNA in the cell cycle was studied by 
flow cytometry. HepG2 cells (2×105) were seeded in 6-well 
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
56
.9
7.
55
 o
n 
11
-J
ul
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2019:14submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2210
Yuan et al
plates and were treated with different formulations of DOX 
(10 µM), DOX+PSO (10 and 20 µM), or DOX+P-LPNs 
(10 and 20 µM) for 48 hours. Cells treated with only medium 
were used as controls. The cells were trypsinized, washed 
with PBS, and fixed in cold 75% (v/v) ethanol solution 
at -20°C overnight. Samples were stained with cell cycle 
reagent containing PI/RNAse (BD Biosciences Pharmingen, 
Shanghai, China) and analyzed using a flow cytometer 
(FACSVerse BD).
rOs formation assay
The intracellular levels of ROS were evaluated using 
2′,7′-dichlorodihydroluorescein diacetate (DCFH-DA). 
The HepG2 cells (2×105) were seeded in a 6-well plate 
and treated with different formulations of DOX (10 µM), 
DOX+PSO (20 µM), and DOX+P-LPNs (20 µM) for 
48 hours. The cells were trypsinized, washed with PBS, and 
incubated with 0.5 mL of medium containing 5 µM of the 
ROS-sensitive probe DCFH-DA at 37°C for 20 minutes. 
Cells were subsequently collected by centrifugation and 
washed three times with cell culture medium without 
FBS. All samples were analyzed by the flow cytometer 
(FACSVerse BD).
Depolarization of mitochondrial membrane 
potential (ΔΨm)
Mitochondrial membrane potential (ΔΨm) was determined 
with a JC-1 reagent. JC-1 is a lipophilic cationic dye that 
selectively enters mitochondria. Depolarization of ΔΨm was 
quantified as an increase in the percentage of depolarized 
cells, which reflected a decrease in JC-1 aggregates and 
an increase of monomer when the inner mitochondrial 
membrane was depolarized.
HepG2 cells (2×105) were seeded in a 6-well plate 
and treated with different formulations of DOX (10 µM), 
DOX+PSO (10 µM or 20 µM), and DOX+P-LPNs (10 µM 
or 20 µM) for 48 hours. JC-1 staining solution (0.5 mL), 
at a concentration of 1 mg/mL, was added to each sample 
and incubated for 20 minutes at 37°C. Subsequently, the 
cells were washed three times with cell culture medium 
without FBS and prepared for flow cytometry (FACS-
Verse BD). Platelet bound JC-1 monomers (FL1) and 
JC-1 aggregates (FL2) were analyzed as FL1–FL2 dot 
plots.28,29
Western immunoblotting
HepG2 cells (2×106) were seeded in 100 mm2 dishes (Corning 
Inc., Corning, NY, USA) and treated with different formu-
lations of DOX (10 µM), DOX+PSO (10 and 20 µM), and 
DOX+P-LPNs (10 and 20 µM) for 48 hours. Subsequently, the 
cells were harvested in RIPA lysis buffer, and protein quan-
titation was done using the BCA assay (Thermo Fisher Life 
Technologies, MA, USA). The protein samples (20–60 µg) 
were separated by 8%–15% SDS-PAGE and transferred to 
polyvinylidene fluoride membranes. Membranes were incu-
bated with rabbit primary antibodies (as specified in figure 
legends) (1:1,000 dilutions) at 4°C overnight, subsequently 
washed with PBS containing 0.5% Tween-20, and probed 
with horseradish peroxidase-conjugated goat anti-rabbit 
immunoglobulin (Abcam, Cambridge, UK) (1:6,000 dilution) 
for 60 minutes at room temperature. The immune complexes 
were detected by chemiluminescence (4A Biotech Co., Ltd, 
Beijing, China) and visualized by ChemiDoc XRS (Bio-Rad, 
CA, USA). The intensity of the band for each protein was 
normalized to that of GAPDH.
statistical analysis
Quantitative data were expressed as mean ± standard error of 
the mean (SEM). Statistical significance in different groups 
was determined by paired Student’s t-test and one-way 
ANOVA as appropriate using GraphPad Prism 6.0 software 
(GraphPad Software Inc, CA, USA). P,0.05 was considered 
to be statistically significant.
Results
Physicochemical characterization of P-lPNs
The lipid-polymer nanocarrier system was used to deliver 
PSO, and the properties of both unloaded LPNs and PSO-
loaded LPNs were characterized as shown in Table 1 and 
Figure 1. The particle sizes were ~65 nm (Figure 1A), with 
zeta potentials of -28 mV, and polydispersity indices of 
0.24. TEM images indicated that the nanoparticles show 
a well-defined spherical shape with a uniform particle 
diameter and no adhesion (Figure 1B). The PSO-loaded 
lipid-polymer nanocarrier system was designed to hold a 
hydrophobic core containing polymer and drug, as well 
as the hydrophilic lipid layer shell.30 Moreover, PSO was 
efficiently loaded into LPNs, with a drug loading of 2.08% 
and an encapsulation efficiency of 72.2%. The drug release 
profiles from P-LPNs are shown in Figure 1C. Non encap-
sulated PSO was completely released from the dialysis bag 
into surrounding PBS within 24 hours, the P-LPNs showed 
sustained release with a cumulative release of PSO exceed-
ing 90% after 96 hours.
In vitro cytotoxicity of PsO and lPNs
The cytotoxicity of free PSO and P-LPNs in HepG2 cells 
was assessed by MTT assays using a 48 hours exposure time. 
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Table 1 Nanoparticle properties of unloaded lPNs and P-lPNs
LPN formulations Size (nm) Zeta potential (mV) Polydispersity index Encapsulation efficiency (%)a Drug loading (%)b
Unloaded lPNs 62.1 (2.7) -29.31 (1.7) 0.22 (0.06) – –
P-lPNs 64.8 (3.2) -27.86 (2.1) 0.24 (0.04) 72.20 (2.8) 2.08 (0.11)
Notes: aEncapsulation efficiency = (total drug in nanoparticle - free drug)/total drug in nanoparticle ×100%. bDrug loading = encapsulated drug/total amount of drug in the 
nanoparticle ×100%. Data is shown as mean (seM) with n=3.
Abbreviations: lPN, lipid-polymer hybrid nanoparticle; P-lPN, PsO-loaded lipid-polymer hybrid nanoparticle; seM, standard error of the mean.
Figure 1 Physicochemical characterization of the P-lPNs. 
Notes: (A) Particle size distribution of P-lPNs was measured by dynamic light scattering spectroscopy. (B) TeM imaging of the P-lPNs. (C) In vitro drug release profiles of 
free PsO and P-lPNs in PBs (0.01 M, ph 7.4) containing 0.5% (w/v) Tween-80.
Abbreviations: P-lPN, PsO-loaded lipid-polymer hybrid nanoparticle; PsO, psoralen; TeM, transmission electron microscopy.
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At concentrations below 40 µM, neither the modulator 
PSO nor P-LPNs produced a cytotoxic effect on HepG2/
ADR cells (Figure 2A). The DOX concentration needed to 
kill 50% of the cells (IC
50
) was 0.32±0.06 µM for sensitive 
HepG2 (HepG2/S) cells, and 61.7±9.3 µM in HepG2/ADR 
cells. This indicates that HepG2/ADR cells were 192-fold 
resistant to DOX (Figure 2B and C). Co-administration of 
DOX and PSO (20 µM) on HepG2/S cells did not show 
a higher toxicity than DOX treatment alone (Figure 2B). 
Co-administration of DOX and P-LPNs (equivalent to 
20 µM PSO) exhibited significantly higher cytotoxicity 
in HepG2/ADR cells compared to free DOX (P,0.01) or 
DOX+PSO (P,0.05) (Figure 2C). This demonstrates that 
co-administration of DOX and P-LPNs is superior to the 
individual components.
analysis of cell apoptosis
The ability of free drugs and the NP formulations to elicit 
an apoptotic response in vitro were measured with flow 
cytometry (Figure 2D–G). Co-administration of DOX and 
PSO on the HepG2/ADR cell resulted in extensive apoptosis 
after 48 hours; in contrast, there was no response with a 
shorter 24 hours incubation (Figure 2D and E). There was, 
however, a greater effect of DOX+P-LPNs compared to the 
free DOX or DOX+PSO treatment, at both 24 and 48 hours. 
This suggested that the nanoformulation enhanced the 
PSO-induced apoptosis in HepG2/ADR cells.
cellular uptake of DOX
By taking advantage of the intrinsic fluorescence properties 
of DOX, quantitative analysis of cellular DOX uptake for 
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Figure 2 cytotoxicity of drug and nanoparticle combinations. 
Note: (A) cell viability in vitro on hepg2/aDr cells at a PsO equivalent concentration ranging from 2.5 to 40 µM. (B) cytotoxicity of DOX, DOX+PsO, 
and DOX+P-lPNs on hepg2/s cells. (C) cytotoxicity of DOX+PsO and DOX+P-lPNs on hepg2/aDr cells in comparison with free DOX. Percent survival 
was compared to that of untreated controls and expressed as a percentage of these controls. (D and E) apoptosis assay of hepg2/aDr cells after incubation 
with DOX, DOX+PsO, and DOX+P-lPNs over 24 hours. (F and G) apoptosis assay of hepg2/aDr after incubation with DOX, DOX+PsO, and DOX+ 
P-lPNs over 48 hours.*P,0.05, **P,0.01, ***P,0.001.
Abbreviations: DOX, doxorubicin; lPN, lipid-polymer hybrid nanoparticle; P-lPN, PsO-loaded lipid-polymer hybrid nanoparticle; PsO, psoralen.
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Figure 3 Cellular uptake of DOX and cell cycle distribution measured by flow cytometry. 
Note: (A and B) cellular uptake of free DOX, DOX+PsO, DOX+P-lPNs, and DOX+Verapamil in hepg2/aDr cells. DOX+Verapamil vs DOX. (C and D) cell 
cycle distribution of HepG2/ADR cells measured by flow cytometry, after being treated with formulations of DOX, DOX+PsO, and DOX+P-lPNs for 48 hours. 
****P,0.0001.
Abbreviations: DOX, doxorubicin; lPN, lipid-polymer hybrid nanoparticle; P-lPN, PsO-loaded- lipid-polymer hybrid nanoparticle; PsO, psoralen.
the different formulations was measured in HepG2/ADR 
cells by flow cytometry. The activity of P-gp was inhibited 
with Verapamil to ascertain the effect of the drug efflux 
pump. Uptake of DOX is presented as mean fluorescence 
intensity (MFI) per cell. As shown in Figure 3A and B, 
the MFI for DOX+PSO in solution or in nanoparticle were 
not significantly different compared to DOX treatment 
alone. This was despite the significant effect of Verapamil 
(P,0.0001) on DOX accumulation. This suggests that PSO 
or P-LPNs do not potentiate the cytotoxic effect of DOX by 
increasing its cellular uptake.
cell cycle analysis
To further investigate the mechanism of apoptosis, cell cycle 
studies were done on HepG2/ADR cells using flow cytometry 
(Figure 3C and D). The effects of treatment with DOX, a 
combination of DOX and PSO in solution, or in nanoparticle 
formulations, on the cell cycle were assessed. There was no 
significant difference in the cell cycle distribution between 
G0/G1, S, and G2/M phase of all treated groups compared 
to controls. The average percentage of cells in G0/G1 phase 
was 50%–55%, S phase cells 15%–20%, and G2/M phase 
cells were 20%–30%. These results indicate that PSO and 
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the P-LPNs did not have any direct effect on cell cycle dis-
tribution. In addition, the PSO-enhanced apoptotic effect 
was not caused by cell cycle arrest in the HepG2/ADR cells.
rOs production
The levels of ROS in HepG2 and HepG2/ADR cells were 
assessed following incubation with combinations of DOX, 
PSO, and nanoparticles. Figure 4A and B demonstrated that 
levels of ROS in untreated HepG2/S cells were significantly 
(P,0.0001) higher than that in HepG2/ADR. A significant 
increase in ROS (ie, DCF fluorescence) in the resistant 
HepG2/ADR cells was observed after incubation with DOX, 
DOX+PSO, and DOX+P-LPNs compared to untreated cells. 
The greatest increase in ROS was observed for treatment 
with DOX+P-LPNs, wherein the levels were similar to that 
observed in the drug sensitive HepG2 cells.
effects of P-lPNs on mitochondrial 
membrane potential
Mitochondria and the integrity of their inner membrane play 
a key role in the apoptotic pathway. An increased produc-
tion of ROS results in depolarization of the mitochondrial 
membrane potential (ΔΨm).31,32 Due to the effects of DOX, 
PSO, and P-LPN formulations on ROS levels, their potential 
to alter ΔΨm in HepG2/ADR cells was measured with the 
fluorescent probe JC-1. As demonstrated in Figure 4C and D, 
treatment with the different formulations resulted in a sig-
nificant loss in mitochondrial ΔΨm. The formulation of ?????
???????????????
?? ????????? ??????????????????????????????????????
??????? ? ?
?? ??????????????????????????????????????????????? ??????????????????
????????????????????????????????????????????
?????????? ?????????????
??? ??? ????????? ? ????
??
?????????? ?????????????????????????????????????????????????????????
?????
???
???
???
?????? ???
???????
??? ???? ?
???
???
???
?????? ???
?????????
??? ???? ?
???
???
???
?????? ???
?????????????
??? ???? ????
???
???
?????? ???
?????????????
??? ???? ?
???
???
???
?????? ???
?????????????
??? ???? ?
???
???
???
?????? ???
?????????????
??? ???? ?
? ?
? ?
Figure 4 Drug and nanoparticle effects on rOs and mitochondrial potential. 
Note: (A) ROS content of HepG2 cells measured by flow cytometry, after treatment with formulations of DOX, DOX+PsO, and DOX+P-lPNs for 48 hours. hs was referred to 
hepg2/s cell. (B) The ROS content ensuing from different treatments are presented as mean fluorescence intensity values. (C) The mitochondrial membrane potential in hepg2/
aDr cells was determined by the Jc-1 dye after incubation with various formulations of DOX, DOX+PsO, and DOX+P-lPNs for 48 hours. (D) The mitochondrial membrane 
potential is expressed as the fluorescence ratios 488/570 and 488/525 nm (aggregates to monomer). *P,0.05, **P,0.01, ***P,0.001, ****P,0.0001.
Abbreviations: DOX, doxorubicin; lPN, lipid-polymer hybrid nanoparticle; P-lPN, PsO-loaded lipid-polymer hybrid nanoparticle; PsO, psoralen.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f N
an
om
ed
ici
ne
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
56
.9
7.
55
 o
n 
11
-J
ul
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2215
Yuan et al
DOX+PSO caused a lower ΔΨm than DOX treatment alone. 
However, the largest collapse in mitochondrial membrane 
potential was produced by treatment with DOX+P-LPNs.
analysis of P-lPNs on expression of P-gp
The resistant phenotype in HepG2/ADR cells was conferred 
by expression of P-gp, which was absent in the drug-sensitive 
parental line HepG2/S (Figure 5A and B). Moreover, as 
shown in lanes 3–7, treatment with combinations of DOX, 
DOX+PSO, and DOX+LPN did not alter the expression of 
P-gp in the HepG2/ADR cells.
analysis of P-lPNs on apoptosis pathways
Increased ROS and decreased mitochondrial ΔΨm are early 
indicators of an apoptotic effect. To determine whether the 
complete process was initiated, the levels of critical mito-
chondrial marker proteins were measured. As demonstrated 
in Figure 5C–F, PSO and the P-LPNs appeared to exert their 
cytotoxic activity by inducing mitochondrial apoptosis.33,34 
Co-administration of DOX and P-LPNs decreased the ratio 
of Bcl-2 to Bax (Figure 5C and D) and was associated with 
elevated levels of cytochrome c (Figure 5C–E), compared to 
all other formulations. The results suggest that the combina-
tion of DOX with P-LPNs may induce apoptosis and was 
supported by the effects on the downstream apoptotic protein 
caspase3 (Figure 5C–F). Figure 5C demonstrates that the 
lower concentration of PSO (10 µM) in the DOX+PSO or 
DOX+P-LPNs treatments was less effective in causing cleav-
age of caspase3. In contrast, the inclusion of a higher PSO 
concentration (20 µM) induced significantly more extensive 
cleavage of caspase3 in HepG2/ADR cells.
Discussion
PSO displays anticancer activity in vitro; however, due to its 
low solubility, the compound has poor bioavailability. The 
objective of this investigation was to ascertain whether the 
effectiveness of PSO could be improved using lipid-polymer 
hybrid nanoparticles to encapsulate PSO. The P-LPNs were 
characterized with diameters of 65 nm and a negative zeta 
potential (-28 mV). TEM confirmed the spherical surface 
and the uniform distribution of nanoparticles and a delayed 
release of cargo.
???? ???????????????????????????? ? ??????????????????????????????????????????????????????????????????????
? ?? ?? ??????? ????????????????????? ??????????????????????????????????????????????????????????????????????? ?? ? ?????? ???????????????????????? ????????? ?????????????????????????????????????????????????????????????????????
???????????????? ???????????? ??
? ???????????????????????????????????????????????????????????????????????????
? ? ? ? ? ? ?????????????????????????????????????????????
?????????? ? ? ? ? ? ??
Figure 5 Western blotting analysis of P-glycoprotein and apoptotic proteins. 
Note: (A) The expression of P-gp was detected by Western blotting. lane 1 represents hepg2/s cells without treatment, lanes 2, 3, 4, 5, 6, and 7 represent the untreated 
control, free DOX (10 µM), DOX+PsO (10 µM), DOXµPsO (20 µM), DOX+lPNs (10 µM), DOX+lPNs (20 µM) treated hepg2/aDr cell. (B) relative content of P-gp 
compared to gaPDh. (C) relative content of Bcl-2/Bax. (D) The expression of Bcl-2/Bax, cytochrome c, and caspase3 (total and cleaved) was detected by Western blotting. 
lanes 1, 2, 3, 4, 5, and 6 represent the untreated control, free DOX (10 µM), DOX+PsO (10 µM), DOX+PsO (20 µM), DOX+lPNs (10 µM), DOX+lPNs (20 µM) treated 
hepg2/aDrcell. (E) relative content of cytochrome c/gaPDh. (F) relative content of cl-caspase3/caspase3. *P,0.05, **P,0.01.
Abbreviations: DOX, doxorubicin; lPN, lipid-polymer hybrid nanoparticle; P-gp, P-glycoprotein; PsO, psoralen.
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Co-administration of DOX and P-LPNs was observed to 
decrease the viability of HepG2/ADR cells compared to treat-
ment with free DOX or DOX+PSO. It has previously been 
shown that PSO induced KB cell death through apoptosis.35 
P-LPNs elicited an apoptotic effect on HepG2/ADR cells 
without any alteration to the cell cycle. This was in contrast 
to observations of PSO arresting HaCaT keratinocyte cells in 
the S phase of the cell cycle and preventing cell progression 
from G1 into S phase in MCF-7/ADR breast cancer cells.36,37 
These differences in PSO effects are likely explained by 
altered signaling pathways between the three cell types.
Over expression of P-gp confers resistance to DOX by 
mediating its active efflux. Despite the ability of PSO and 
P-LPNs to enhance the cytotoxicity of DOX in resistant 
HepG2/ADR cells, the formulations did not affect DOX 
accumulation. In addition, the level of P-gp expression was 
not altered in the presence of PSO or P-LPNs. However, 
Jiang et al38 demonstrated that the intracellular drug accu-
mulation was significantly increased in MCF7/ADR cells 
after treatment with PSO, whereas the P-gp expression at 
the mRNA or protein level was unaffected.37,38 Hsieh et al11 
revealed that PSO suppressed P-gp activity and decreased 
mRNA and proteins levels of P-gp in A549/D16 cell. 
However, the effects of P-gp on the extent of drug accumu-
lation are highly dependent on its level of expression and 
the respective concentration of drug. Consequently, the cell 
phenotype provides a more accurate measure of its influence.
In the present study, DOX+P-LPNs treatment was also 
associated with elevated ROS levels and a concomitant depo-
larization of mitochondrial ΔΨm. Wang et al39 developed a 
lipid membrane-coated silica-carbon hybrid nanoparticle 
that targeted mitochondria to produce ROS and inhibited 
the production of ATP in NCI/AdrRES cells. The loss of 
ATP resulted in downregulation of efflux pumps and a loss 
of multidrug resistance. Although the DOX+P-LPNs treat-
ment did not alter P-gp expression, there were marked effects 
on mitochondrial function in HepG2/ADR cell. Targeting 
mitochondria, which provided energy for tumor cells, may 
induce cancer cell death and overcome drug resistance pro-
duced by efflux pumps. In fact, delivering apoptotic agents 
to mitochondria has previously been shown as an effective 
strategy against the resistant phenotype.27,40,41
Increased generation of ROS causes oxidative stress, lipid 
peroxidation, loss of cytochrome c from permeabilized mito-
chondria, and activation of caspase cascade. This was also 
observed for DOX+P-LPNs and extended to downregulated 
bcl-2 expression, improved cytochrome c, and promoted the 
cleavage of caspase3. Bcl-2 and Bax are apoptosis regulators 
belonging to the Bcl-2 family and regulate apoptotic 
mediators, such as cytochrome c, by controlling the perme-
ability of the mitochondrial membrane.42,43 Alternate lipid-
polymer hybrid nanoparticles have also been demonstrated 
to induce a similar mitochondrial apoptotic pathway.44 
Conclusion
In summary, we developed a lipid-polymer hybrid nanopar-
ticle to encapsulate PSO, which could enhance the treatment 
efficiency of chemotherapy drugs in an HepG2/ADR cell, 
by increasing ROS level and improving the mitochondrial 
apoptotic pathway. Targeting the mitochondria, rather than 
modulating drug efflux pump activity, was responsible for the 
effectiveness of the nanoparticles in resistant cells. Based on 
these results, it is inferred that lipid-polymer hybrid nanopar-
ticles hold promise as a drug delivery system for effective 
chemotherapy. Further studies on the in vivo efficiency of 
P-LPNs are required to ascertain how the encapsulation 
affects pharmacokinetic profiles.
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